ADORA2A and Crohn ileitis: A2AR activity has been associated with amelioration of spontaneous ileitis and administration of the A2AR agonist ATL-146e significantly reduced the intestinal mucosa inflammation, leukocyte infiltration in the gut and release of proinflammatory cytokines (48).